Evidence map›Paper›PMID 20458757›Full record

SynthesisWorld journal of gastroenterology2010

Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

Lynne V McFarland

2 registry-linked trialsAbstract readEditorialMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in World journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 227 papers, 20 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
227citing papers in PubMed, 20 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02637167 phase2unknown statusnot on this mapstarted 2016, after this paper: background citation

GutHeart: Targeting Gut Microbiota to Treat Heart Failure

TypeinterventionalSponsorOslo University HospitalRan2016 to 2019Enrolled150ConditionsSystolic Heart FailureArmsRifaximin, Saccharomyces boulardii
NCT03427515 nacompletednot on this mapstarted 2016, after this paper: background citation

Effect of Supplementation With Saccharomyces Boulardii and Lactobacillus Rhamnosus on Examination-related Stress in Healthy Medical Students: a Randomised, Double-blind, Placebo-controlled Trial

TypeinterventionalSponsorMedical University of LodzRan2016 to 2016Enrolled92ConditionsHealthy, Stress-related Problem, AnxietyArmsLactobacillus rhamnosus GG (ATCC 53103), Saccharomyces boulardii (CNCM I-1079), Placebo
3 · Its place in the literature

Who cites it

227 citing papers in PubMed, 20 syntheses or guidelines pooled it.

  1. Frontiers in nutrition · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Efficacy and safety ofFrontiers in cellular and infection microbiology · 2025
    Pooled it
  6. Efficacy and safety ofFrontiers in cellular and infection microbiology · 2025
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Probiotic sepsis in preterm neonates-a systematic review.European journal of pediatrics · 2022
    Pooled it
  10. Pooled it
  11. Guideline
  12. Pooled it
  13. Probiotics for the prevention of pediatric antibiotic-associated diarrhea.The Cochrane database of systematic reviews · 2019
    Pooled it
  14. Guideline
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

167 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Lynne V McFarland

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article reviews the evidence for efficacy and safety of Saccharomyces boulardii (S. boulardii) for various disease indications in adults based on the peer-reviewed, randomized clinical trials and pre-clinical studies from the published medical literature (Medline, Clinical Trial websites and meeting abstracts) between 1976 and 2009. For meta-analysis, only randomized, blinded controlled trials unrestricted by language were included. Pre-clinical studies, volunteer studies and uncontrolled studies were excluded from the review of efficacy and meta-analysis, but included in the systematic review. Of 31 randomized, placebo-controlled treatment arms in 27 trials (encompassing 5029 study patients), S. boulardii was found to be significantly efficacious and safe in 84% of those treatment arms. A meta-analysis found a significant therapeutic efficacy for S. boulardii in the prevention of antibiotic-associated diarrhea (AAD) (RR = 0.47, 95% CI: 0.35-0.63, P < 0.001). In adults, S. boulardii can be strongly recommended for the prevention of AAD and the traveler's diarrhea. Randomized trials also support the use of this yeast probiotic for prevention of enteral nutrition-related diarrhea and reduction of Helicobacter pylori treatment-related symptoms. S. boulardii shows promise for the prevention of C. difficile disease recurrences; treatment of irritable bowel syndrome, acute adult diarrhea, Crohn's disease, giardiasis, human immunodeficiency virus-related diarrhea; but more supporting evidence is recommended for these indications. The use of S. boulardii as a therapeutic probiotic is evidence-based for both efficacy and safety for several types of diarrhea.

Indexed as

SaccharomycesAdultAnti-Bacterial AgentsContraindicationsDiarrheaEnteral NutritionEvidence-Based MedicineHumansIntestinal DiseasesIntestinesPractice Guidelines as TopicProbioticsTravelTreatment OutcomeAnti-Bacterial Agents

Identifiers

PMID20458757
PMCPMC2868213

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.